Floatz logo

POLY((N-(2-HYDROXYPROPYL)METHACRYLAMIDE)-CO-(METHACRYLOYL-GLY-PHE-LEU-GLY AMIDE WITH O-((TRANS-4-AMINOCYCLOHEXYL)CARBAMOYL)FUMAGILLOL)) (~0.91:0.09 X)

Metastasis

SynDevRx, Inc.OtherPhase 1Dormant
CC
44/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
32/ 100
Competitive Position
81/ 100

Competitive context

171 Active assets in the Metastasis cohort.

Asset / SponsorPhaseRating
FLUOROURACILUM
Ruijin Hospital
Phase 4BBB
Eloxatin
Ruijin Hospital
Phase 4BBB
Irinotecan
Eli Lilly and Company
Phase 4BBB
DEXAMETHASONE
Janssen Research & Development, LLC
Phase 2BBB
Ipilimumab
7 Hills Pharma, LLC
Phase 3BB

View all 50 →

Same molecule, other indications

POLY((N-(2-HYDROXYPROPYL)METHACRYLAMIDE)-CO-(METHACRYLOYL-GLY-PHE-LEU-GLY AMIDE WITH O-((TRANS-4-AMINOCYCLOHEXYL)CARBAMOYL)FUMAGILLOL)) (~0.91:0.09 X) is also rated in:

triple-negative breast carcinomaDormant
CCC
Indicative ·
53 / 100
View asset →
breast cancerDormant
CCC
Indicative ·
50 / 100
View asset →
HR+/HER2-negative Breast CancerDormant
CCC
Indicative ·
48 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →